QuantSoar
HealthcareUpdatedΒ·Data: Yahoo Finance, SEC EDGARΒ·Data delayed ~5 min
SO

Deep Dive SOLV Governance Score Deep Value Discount

NYQ Β· Healthcare Β· Medical Instruments & Supplies

$90.06

+0.24 (+0.27%)

OverviewTechnicalRiskWhaleEarningsOptionsShort InterestESG

SOLV Interactive Price Chart & Trading Signals

SOLV Stock Snapshot β€” Valuation, Risk & Technical Signals

SOLV Key Fundamentals, Analyst Targets & Company Profile

Key Financial Ratios

Market Cap

$15.33B

P/E Ratio

10.98

Forward P/E

12.45

PEG Ratio

1.22

P/B Ratio

3.19

EPS

$8.20

Dividend Yield

β€”

52W Range

$62.38 – $94.16

Beta

0.69

Volume

1.1M

ROE

34.0%

Profit Margin

17.3%

Revenue Growth

2.2%

Gross Margin

54.8%

EV/EBITDA

17.75

Analyst Target

$93.92

The trailing price-to-earnings ratio stands at 11.0x. Forward P/E of 12.5x indicates stable forward expectations. Price-to-book is 3.19x. EV/EBITDA sits at 17.75x. Market capitalization is $15.33B. Revenue is growing at 2.2% on a trailing basis. Earnings are expanding at 3.9%. Profit margins are 17.3%. Return on equity is 34.0%. Beta of 0.69 indicates defensive profile.

Analyst Consensus

Recommendation

Buy

Low Target

$70.00

Mean Target

$93.92

High Target

$113.00

Based on 13 analysts

About SOLV

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

United States20,584 employeesWebsite β†—

Trade SOLV on Interactive Brokers

Low-cost global trading

SOLV Deep Dive Analysis

Bottom Line

Verdict

Undervalued

Best for

Value-oriented investors

Watch out for

None flagged

Data confidence

High

Solventum Corporation (SOLV) trades below our multi-model fair value estimate of $168.02 by approximately 86.6%. Trailing P/E: 11.0x. Profitability signals include profit margin of 17.3% and return on equity of 34.0%. Recent growth metrics show revenue growth of 2.2% and earnings growth of 3.9%. Risk profile: defensive beta of 0.69. Consensus: buy.

SOLV Deep Dive Analysis

Valuation

Undervalued

P/E 11.0x

Price sits below our estimate of fair value.

Growth

Stable

Rev 2.2%

Revenue is moving sideways.

Risk

Low

Beta 0.69

Movement is likely to track the broader market.

Valuation Snapshot

Solventum Corporation (SOLV) trades below our multi-model fair value estimate of $168.02 by approximately 86.6%. The trailing price-to-earnings ratio stands at 11.0x. Forward P/E of 12.5x implies earnings expansion expected. Price-to-sales is 1.8x. Price-to-book is 3.2x. EV/EBITDA sits at 17.8x. Market capitalization is $15.33B.

Why it matters: Buying below fair value can create a margin of safety, but always check earnings quality.

Growth & Profitability

Revenue is growing at 2.2% on a trailing basis. Earnings are expanding at 3.9%. Profit margins are 17.3%. Return on equity is 34.0%. Return on assets is 2.7%.

Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.

Risk Profile

Beta of 0.69 indicates defensive profile. Net debt position is $4.89B.

Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.

Analyst Context

Analyst consensus target of $93.92 implies 4.3% upside. Target range spans $70.00 to $113.00. 13 analysts cover the stock. Consensus recommendation: buy.

Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.

Investor Fit

The combination of undervaluation and moderate risk may suit value-oriented investors.

Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.

Data Methodology & Sources

Market Data (Facts)

  • Price, volume, market cap: Yahoo Finance (delayed ~5 min)
  • P/E, EPS, revenue, debt: Yahoo Finance fundamentals
  • Analyst targets: Yahoo Finance consensus (may lag)
  • Insider trades: SEC EDGAR Form 4 filings

QuantSoar Model (Derived)

  • Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β€” trimmed inverse-variance weighted
  • Margin of Safety = (Fair Value βˆ’ Live Price) / Live Price Γ— 100
  • Composite Score: 40% Value + 30% Momentum + 30% Risk
  • Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.

Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.

SOLV Undervalued

Solventum Corporation (SOLV) trades below our multi-model fair value estimate of $168.02 by approximately 86.6%.

Frequently Asked Questions

ValuationIs SOLV stock overvalued right now?
Our multi-model fair value estimate of $168.02 suggests SOLV may be undervalued by approximately 86.6% at the current price of $90.06.
ValuationWhat is SOLV fair value based on current fundamentals?
Our fair value estimate for SOLV is $168.02, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.
RiskHow risky is SOLV compared with other stocks?
SOLV carries a beta of 0.69 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.
GrowthIs SOLV still growing?
Latest trailing metrics show revenue growth of 2.2% and earnings growth of 3.9%. Profit margins are 17.3%.
AnalystWhat do analysts think about SOLV?
Analyst consensus target is $93.92, implying 4.3% upside. The street recommendation is "buy".
CatalystWhat could change the investment case for SOLV?
Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

Related Stocks

Healthcare

Explore top stocks in this sector

Explore sector β†’

Stock valuation guideMacro risk explained guide
Phasakorn Traklang (Peach)

About the Author

Phasakorn Traklang (Peach) β€” Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.